These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15780611)

  • 21. 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.
    Li W; Hu Y; Li J; Thomason JR; DeVincentis D; Du X; Wu J; Hotchandani R; Rush TS; Skotnicki JS; Tam S; Chockalingam PS; Morris EA; Levin JI
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4546-50. PubMed ID: 19625186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.
    Barta TE; Becker DP; Bedell LJ; Easton AM; Hockerman SL; Kiefer J; Munie GE; Mathis KJ; Li MH; Rico JG; Villamil CI; Williams JM
    Bioorg Med Chem Lett; 2011 May; 21(10):2820-2. PubMed ID: 21507637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability.
    Staas DD; Savage KL; Sherman VL; Shimp HL; Lyle TA; Tran LO; Wiscount CM; McMasters DR; Sanderson PE; Williams PD; Lucas BJ; Krueger JA; Lewis SD; White RB; Yu S; Wong BK; Kochansky CJ; Anari MR; Yan Y; Vacca JP
    Bioorg Med Chem; 2006 Oct; 14(20):6900-16. PubMed ID: 16870455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors.
    Rankovic Z; Cai J; Kerr J; Fradera X; Robinson J; Mistry A; Hamilton E; McGarry G; Andrews F; Caulfield W; Cumming I; Dempster M; Waller J; Scullion P; Martin I; Mitchell A; Long C; Baugh M; Westwood P; Kinghorn E; Bruin J; Hamilton W; Uitdehaag J; van Zeeland M; Potin D; Saniere L; Fouquet A; Chevallier F; Deronzier H; Dorleans C; Nicolai E
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1524-7. PubMed ID: 20149657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
    Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
    Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
    J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
    Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.
    Heim-Riether A; Taylor SJ; Liang S; Gao DA; Xiong Z; Michael August E; Collins BK; Farmer BT; Haverty K; Hill-Drzewi M; Junker HD; Mariana Margarit S; Moss N; Neumann T; Proudfoot JR; Keenan LS; Sekul R; Zhang Q; Li J; Farrow NA
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5321-4. PubMed ID: 19692239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).
    Pochetti G; Montanari R; Gege C; Chevrier C; Taveras AG; Mazza F
    J Med Chem; 2009 Feb; 52(4):1040-9. PubMed ID: 19173605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
    Bezençon O; Bur D; Weller T; Richard-Bildstein S; Remen L; Sifferlen T; Corminboeuf O; Grisostomi C; Boss C; Prade L; Delahaye S; Treiber A; Strickner P; Binkert C; Hess P; Steiner B; Fischli W
    J Med Chem; 2009 Jun; 52(12):3689-702. PubMed ID: 19358611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterocycle-based MMP inhibitors with P2' substituents.
    Pikul S; Dunham KM; Almstead NG; De B; Natchus MG; Taiwo YO; Williams LE; Hynd BA; Hsieh LC; Janusz MJ; Gu F; Mieling GE
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1009-13. PubMed ID: 11327577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
    Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
    Wang X; Sarris K; Kage K; Zhang D; Brown SP; Kolasa T; Surowy C; El Kouhen OF; Muchmore SW; Brioni JD; Stewart AO
    J Med Chem; 2009 Jan; 52(1):170-80. PubMed ID: 19072118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
    Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
    J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.
    Nicolotti O; Catto M; Giangreco I; Barletta M; Leonetti F; Stefanachi A; Pisani L; Cellamare S; Tortorella P; Loiodice F; Carotti A
    Eur J Med Chem; 2012 Dec; 58():368-76. PubMed ID: 23149299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.
    Shi Y; Sitkoff D; Zhang J; Klei HE; Kish K; Liu EC; Hartl KS; Seiler SM; Chang M; Huang C; Youssef S; Steinbacher TE; Schumacher WA; Grazier N; Pudzianowski A; Apedo A; Discenza L; Yanchunas J; Stein PD; Atwal KS
    J Med Chem; 2008 Dec; 51(23):7541-51. PubMed ID: 18998662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2014 Oct; 22(19):5487-505. PubMed ID: 25192810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.